About Gossamer Bio
Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.
Founders and CEO: Faheem Hasnain
Founder and COO: Sheila Gujrathi, M.D
7 articles with Gossamer Bio
Gossamer Bio Inc. (“Gossamer Bio”), today announced the closing of a $230 million Series B.
Since it first launched with $100 million in the bank earlier this year, Gossamer Bio has been on something of a roll.
Aerpio Announces Exclusive License Agreement with Gossamer Bio for AKB-4924, a First in Class Hypoxia-Inducible Factor-1 Alpha Stabilizer in Development for Inflammatory Bowel Disease
The arrangement combines Aerpio’s deep understanding of HIF biology with Gossamer’s experience in inflammation, immunology and inflammatory bowel disease (IBD) drug development.
This morning two companies announced deals that will yield potential benefits to multiple patient populations.
Mr. Giraudo will lead the company’s finance and administrative functions.
1/8/2018A look at the latest startups that have emerged in 2018 so far.
It is not clear what the new company's focus is just yet.